Data show that of patients with prostate cancer, Black men face higher incidence and mortality rates than White men. Recent research has demonstrated that these increased rates may be due to neighborhood distress, chronic stress, and downstream biological effects. A study from Joseph Boyle, PhD, and colleagues published in JAMA Network Open investigated the potential connection between neighborhood disadvantage metrics and prostate tumor RNA expression of stress-related genes. ...
Localized Prostate Cancer
Advertisement
Latest News
For the treatment of localized prostate cancer, guidelines typically recommend the addition of ADT to RT in certain patients.
Drs. Stifelman and Ambinder discuss the novel approaches and adoption challenges of single-port and Da Vinci 5 systems.
Dr. Shore discusses treatment-related adverse events associated with apalutamide and ADT.
Dr. Shore discusses the effects of apalutamide plus ADT in patients with prostate cancer.
Drs. Joshua and Wallis contextualize the Metformin Active Surveillance Trial for management of low-risk prostate cancer.
New research provides evidence of 18F-rhPSMA-7 leading to more favorable disease outcomes for patients with BCR after RP.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content based on prostate cancer types, therapies, and technologies
Conference Coverage
Disitamab vedotin plus pembrolizumab shows promising efficacy, manageable safety in HER2+ aUC, with a 61.1% response rate.
Prognostic and predictive phenotypic biomarkers have been identified for rPFS and OS in de novo mCSPC.
The addition of nivo to trimodality therapy may improve RFS in patients with non-metastatic muscle-invasive bladder cancer.
PFS was improved with nivolumab plus cabozantinib.
In patients with pretreated UC, BL-B01D1 demonstrated manageable safety with encouraging antitumor activity.
Enfortumab vedotin plus pembrolizumab showed consistent PFS and OS benefit across all subgroups.
Advertisement
Advertisement
Trending
Disitamab vedotin plus pembrolizumab shows promising efficacy, manageable safety in HER2+ aUC, with a 61.1% response rate.
Prognostic and predictive phenotypic biomarkers have been identified for rPFS and OS in de novo mCSPC.
The addition of nivo to trimodality therapy may improve RFS in patients with non-metastatic muscle-invasive bladder cancer.
